Speaker Profile

Ph.D., Co-founder and CEO, Gencove Inc.

Joseph Pickrell is the co-founder and CEO of Gencove. With the vision of providing accessible and affordable genomic information, Gencove developed a novel low-pass whole genome sequencing and computational analysis platform for breakthrough biological discovery. Prior to starting Gencove, Dr. Pickrell was a Principal Investigator at the New York Genome Center (NYGC) and Adjunct Assistant Professor in the Department of Biological Sciences at Columbia University. At NYGC, the Pickrell Lab developed novel statistical approaches to transform large-scale genomic data into an improved understanding of human biology and history by understanding natural human variation and molecular and phenotypic consequences. Dr. Pickrell has a Ph.D. in human genetics from the University of Chicago and a B.S. in biology from the University of North Carolina-Chapel Hill. His work has been featured in the New York Times, the Wall Street Journal and has been published in prestigious scientific journals.

Genomic Profiling Showcase:

Gencove is making genomic information ubiquitous through high-volume, cost-sensitive whole genome sequencing and computational analysis software. The Gencove platform provides academic, agriculture, biotech, and pharmaceutical companies genomic insights to impact health and sustainability.

Democratizing Genome Sequencing Through Software
Gencove developed high-throughput, cost-effective, low-pass whole genome sequencing with the potential to connect genomic information to phenotypic outcomes. Dr. Joe Pickrell will describe the Gencove technology platform and show how biotech and pharmaceutical companies are using the platform’s genomic insights.

 Session Abstract – PMWC 2022 Silicon Valley

Track 7, June 28-30

The PMWC 2022 Genomic Profiling Showcase will provide a 15 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.